EUVIMEDEUVIMED entdecken
Crossref

PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma

Dong Hyun Kim, Jiwon Koh, Jong Seok Ahn, Jimin Moon, Mingu Kang, Gahee Park, Yoojoo Lim, Chan-Young Ock, Yoon Kyung Jeon, Kyeong Cheon Jung, Soon-Hyun Ahn, Eun-Jae Chung und 2 weitere

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · 2026

DOI: 10.1016/j.oooo.2025.11.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2026. Verfasst von Dong Hyun Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National U…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Research Foundation, Korea Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) expression and immune phenotype (IP) are potential predictive biomarkers for immune checkpoint inhibitors (ICIs) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This study evaluated the predictive value of combining PD-L1 expression and IP in R/M HNSCC. STUDY DESIGN: Forty-one R/M HNSCC patients treated with ICI were included. PD-L1 expression was evaluated using the standardized 22C3 pharmDx assay. IPs were assessed using Lunit SCOPE IO, an artificial intelligence-powered tumor-infiltrating lymphocyte analyzer. RESULTS: Thirty-nine patients (95.1%) were classified as PD-L1 positive (combined positive score ≥1). Overall, 27 (65.9%) had desert IP. PD-L1 expression and IP were combined to classify patients into 3 groups: group A, negative PD-L1; group B, positive PD-L1 with desert IP; group C, positive PD-L1 with non-desert IP. The median progression-free survival (PFS) was 1.2 months in group A, 2.1 months in group B, and 12.1 months in group C (P = .015). In multivariate Cox analysis, PD-L1 expression combined with IP was an independent factor for PFS, with a hazard ratio of 0.14 (P = .018) in group C and 0.37 (P = .186) in group B, relative to group A. CONCLUSIONS: In R/M HNSCC, integrating IP with PD-L1 expression may enhance prediction of ICI outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmune Checkpoint InhibitorsSquamous Cell Carcinoma of Head and NeckNeoplasm Recurrence, LocalHead and Neck NeoplasmsHumansMaleFemaleMiddle AgedAgedBiomarkers, TumorPhenotypeAdultTreatment OutcomePrognosisRetrospective StudiesAged, 80 and overNeoplasm MetastasisPredictive Value of Tests

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Lunit Inc, Seoul, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: bhum…

Förderung

  • National Research Foundation
  • Korea Ministry of Science and ICT

Zitieren

APA

Kim, D. H., Koh, J., Ahn, J. S., Moon, J., Kang, M., Park, G., Lim, Y., Ock, C. Y., Jeon, Y. K., Jung, K. C., Ahn, S. H., Chung, E. J., Kwon, S. K., & Keam, B. (2026). PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. https://doi.org/10.1016/j.oooo.2025.11.018

Vancouver

Kim DH, Koh J, Ahn JS, Moon J, Kang M, Park G, et al. PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2026. doi:10.1016/j.oooo.2025.11.018

BibTeX
@article{Kim2026,
  author = {Kim, Dong Hyun and Koh, Jiwon and Ahn, Jong Seok and Moon, Jimin and Kang, Mingu and Park, Gahee and Lim, Yoojoo and Ock, Chan-Young and Jeon, Yoon Kyung and Jung, Kyeong Cheon and Ahn, Soon-Hyun and Chung, Eun-Jae and Kwon, Seong-Keun and Keam, Bhumsuk},
  title = {PD-L1 expression combined with immune phenotype is a potential predictor of outcome with PD-1 inhibitor monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma},
  journal = {Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology},
  year = {2026},
  doi = {10.1016/j.oooo.2025.11.018}
}
Kostenlos starten →